Radius (RDUS) to Acquire Rights for Cannabidiol Oral Solution
Radius Health, Inc. RDUS announced a definitive agreement to acquire the global development and commercialization rights of Benuvia Therapeutics Inc.’s synthetic cannabidiol oral solution (“RAD011”).
RAD011 is a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases.
The initial indication, for which the candidate will be evaluated, is Prader-Willi syndrome (“PWS”).
Radius intends to begin a phase II/III stud...